Read this first
This is plain-language harm-reduction information, not medical advice. Peptides discussed here are research compounds; most are not approved for human use. People will use them either way — we would rather they have the facts.
On 31 March 2026 the US FDA published a warning letter to Gram Peptides, a California seller. It is a clear statement of how the agency treats the "research use only" label that is common on peptide websites.
What the letter says
According to the FDA's letter, the company sold retatrutide (marketed as a "GLP-1-R peptide"), tirzepatide (marketed as a "GLP-2 peptide") and bacteriostatic water for injection. The FDA concluded these are unapproved new drugs, in violation of sections 301(d) and 505(a) of the Federal Food, Drug, and Cosmetic Act, because they lack FDA approval and are not generally recognised as safe and effective.
On the research-use label, the FDA was direct. Although the products carried statements that they were "not intended for human consumption", the agency pointed to website claims about appetite suppression, glucose handling and body-weight reduction as evidence that they were intended as drugs. In other words, the label did not outweigh how the product was actually marketed.
The FDA also stated that injectable drug products can pose risks of serious harm because they bypass the body's natural defences against toxins and microorganisms, potentially causing serious and life-threatening conditions. The company had 15 working days to respond with corrective steps or face possible seizure and injunction.
A wider pattern
A law-firm summary from Health Law Alliance reports that in September 2025 the FDA sent more than 50 warning letters about compounding violations, and a separate series of letters about peptides sold as research use only where the advertising indicated human use. It lists semaglutide, tirzepatide and retatrutide among the products named, and also mentions BPC-157. The same summary says the FDA set up Import Alert 66-80 for GLP-1 active ingredients and stepped up unannounced inspections of foreign manufacturers of those ingredients.
Why it matters if you are considering peptides
- "Research use only" is not a safety standard. It does not mean tested, sterile, or correctly dosed, and the FDA says it will not accept the label as a defence for products clearly sold for human use.
- Sellers who are being warned today may be gone, rebranded or out of stock tomorrow, which is a risk if you have already planned a regimen around them.
- These letters are about sellers, not buyers. They tell you how the regulator views the product, not that the product has been tested.
A vendor that says "not for human consumption" in the small print while describing weight-loss or healing effects on the product page is exactly the pattern the FDA targeted in this letter.
What is still unknown
We do not know how Gram Peptides responded, or whether the FDA took further action. A warning letter is not a court finding. Nor does the letter test the contents of the products, so it says nothing about what was actually in the vials.
See our pages on retatrutide and tirzepatide for what is and is not known about each.
Common questions
Does a "research use only" label make a peptide legal to sell for people?
According to the FDA's March 2026 letter, no. The agency looks at how the product is marketed, and treated claims about appetite and body weight as showing intended drug use.